FDA issues CRL to Repros Therapeutics

Repros Therapeutics Inc. (Nasdaq: RPRX) received a Complete Response Letter from the Food and Drug Administration for its secondary hypogonadism treatment enclomiphene sending the stock price plummeting 66 cents to close at $1.74.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.